The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Yehia, Baligh R ^a,b,c   Schranz, Asher J ^d   Umscheid, Craig A ^a,b,c   Lo Re III, Vincent ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C ANTIBODY; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; GENOTYPE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH EDUCATION; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MASS SCREENING; OUTPATIENT CARE; PATIENT CARE; PATIENT EDUCATION; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED STATES; AMBULATORY CARE; COMPLICATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; LIVER; LIVER CIRRHOSIS; META ANALYSIS; PATHOLOGY; VIROLOGY;

AMBULATORY CARE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; RNA, VIRAL; UNITED STATES;

EID: 84903795463     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101554     Document Type: Article

References (45)

1. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ (2011) The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 52: 793-800.
2. Vital Signs (2011) HIV prevention through care and treatment - United States. MMWR Morb Mortal Wkly Rep 60: 1618-1623.
3. Hull MW, Wu Z, Montaner JS (2012) Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS 7: 579-586.
4. Mahle Gray K, Tang T, Shouse L, Li J, Mermin J, et al. (2013) Using the HIV surveillance system to monitor the National HIV/AIDS Strategy. Am J Public Health 103: 141-147.
5. Yehia B, Frank I (2011) Battling AIDS in America: an evaluation of the National HIV/AIDS Strategy. Am J Public Health 101: e4-8.
6. Fleishman JA, Yehia BR, Moore RD, Korthuis PT, Gebo KA, et al. (2012) Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr 60: 249-259.
7. Mugavero MJ, Amico KR, Horn T, Thompson MA (2013) The State of Engagement in HIV Care in the United States: From Cascade to Continuum to Control. Clin Infect Dis 57(8):1164-71.
8. Insitute of Medicine (2010) Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC.
9. Edlin BR (2011) Perspective: test and treat this silent killer. Nature 474: S18-19.
10. Brau N (2013) Evaluation of the hepatitis C virus-infected patient: the initial encounter. Clin Infect Dis 56: 853-860.
11. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Disease (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
12. Lo Re V III, Teal V, Localio AR, Amorosa VK, Kaplan DE, et al. (2011) Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med 155: 353-360.
13. Yee HS, Chang MF, Pocha C, Lim J, Ross D, et al. (2012) Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 107: 669-689; quiz 690.
14. US Department of Health and Human Services (2011) Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care & Treatment of Viral Hepatitis. Washington, DC. pp. 1-76.
15. Aghemo A, De Francesco R (2013) New horizons in Hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 58(1):428-38.
16. Holmberg SD, Spradling PR, Moorman AC, Denniston MM (2013) Hepatitis C in the United States. N Engl J Med 368(20):1859-1861.
17. Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB (2012) Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol 56: 320-325.
18. Umscheid CA (2013) A Primer on Performing Systematic Reviews and Meta-analyses. Clin Infect Dis 57: 725-734.
19. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, et al. (2011) A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 31 Suppl 2: 30-60.
20. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. (Pubitemid 34746062)
21. OpenMeta[Analyst] (2012). Accessed at http://www.cebm.brown.edu/open- meta. on Dec 15, 2013.
22. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, et al. (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705-714. (Pubitemid 46780630)
23. Arora S, Thornton K, Murata G, Deming P, Kalishman S, et al. (2011) Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 364: 2199-2207.
24. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, et al. (2011) A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C. Clin Gastroenterol Hepatol 9: 509-516.e501.
25. Groessl EJ, Liu L, Ho SB, Kanwal F, Gifford AL, et al. (2012) National patterns and predictors of liver biopsy use for management of hepatitis C. J Hepatol 57: 252-259.
26. Kanwal F, Hoang T, Chrusciel T, Kramer JR, El-Serag HB, et al. (2012) Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clin Gastroenterol Hepatol 10: 1270-1277.
27. Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, et al. (2010) Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med 153: 231-239.
28. Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V (2010) Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Value Health 13: 479-486.
29. Moorman AC, Gordon SC, Rupp LB, Spradling PR, Teshale EH, et al. (2013) Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis 56: 40-50.
30. Russell M, Pauly MP, Moore CD, Chia C, Dorrell J, et al. (2012) The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan. Hepatology 56: 1223-1230.
31. Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A (2013) Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat 20: 550-555.
32. Denniston MM, Klevens RM, McQuillan GM, Jiles RB (2012) Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology 55: 1652-1661.
33. Moyer VA, on behalf of the USPSTF (2013) Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 159(5): 349-57.
34. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, et al. (2012) Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 61: 1-32.
35. Thomas DL (2012) Advances in the treatment of hepatitis C virus infection. Top Antivir Med 20: 5-10.
36. Garcia-Tsao G (2001) Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 120: 726-748.
37. Bruix J, Sherman M, American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
38. Chou R, Wasson N (2013) Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 158: 807-820.
39. Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, et al. (2013) Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol 11: 1503-1510.
40. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, et al. (2012) The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 156: 263-270.
41. El Khoury AC, Vietri J, Prajapati G (2012) The burden of untreated hepatitis C virus infection: a US patients' perspective. Dig Dis Sci 57: 2995-3003.
42. Veterans Health Administration. (2009) The State of Care for Veterans with HIV/AIDS. Available: http://www.hiv.va.gov/provider/policy/state-of-care/. Accessed 2013 Dec 15.
43. Butt AA, Khan UA, Shaikh OS, McMahon D, Dorey-Stein Z, et al. (2009) Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 10: 25-32.
44. Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK (2006) Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment Pharmacol Ther 24: 585-591. (Pubitemid 44127839)
45. Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, et al. (2007) Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 46: 1741-1749.